SM 309515
Alternative Names: SM-309515Latest Information Update: 08 Feb 2008
At a glance
- Originator Dainippon Sumitomo Pharma
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for HIV-1 infections in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 26 Sep 2003 Preclinical trials in HIV-1 infections in Japan (unspecified route)